8-K: Minerva Neurosciences Appoints Dr. Kaul to Board, Bolsters R&D

Minerva Neurosciences strengthens its Board and clinical development expertise with the appointment of Dr. Inderjit Kaul, a seasoned drug development leader, and engages him as a consultant for roluperidone's Phase 3 trial.

Summary

• The Board of Directors increased its size to six members and appointed Dr. Inderjit Kaul, M.D., MPH, as a Class II director, with his initial term expiring at the Company's 2025 Annual Meeting of Stockholders.
• Dr. Kaul will receive an annual cash retainer of $40,000 for his board service, prorated for the remainder of 2025, and an initial option grant to purchase 9,500 shares of common stock, vesting quarterly over three years.
• A consulting agreement was entered into with Dr. Kaul, effective November 14, 2025, for assistance with clinical trial workstreams and related services, requiring approximately 25 to 30 hours per month at a rate of $450 per hour.
• Under the consulting agreement, Dr. Kaul will be granted an option to purchase shares representing 0.7% of the 'Share Total' (which includes outstanding shares, shares from Series A conversion, existing options, and other potential issuances), subject to stockholder approval for an increase to the share reserve.
• The consultant option's vesting schedule is tied to key milestones: 25% after one year of continuous service, 45% upon public announcement of statistically significant primary endpoint achievement in the Phase 3 confirmatory trial of roluperidone at the 12-week timepoint, and 30% upon public announcement of safety data from the 40-week relapse assessment phase.
• The Company recently raised up to $200 million in a private placement to fund the confirmatory Phase 3 trial for roluperidone, resubmission of its New Drug Application (NDA), and preparation for US commercial launch, if approved.

Sentiment

Score: 7

Explanation: The appointment of a highly experienced director and consultant with a strong track record in schizophrenia drug development is a positive step for Minerva Neurosciences, especially given the recent capital raise and focus on a significant unmet medical need. However, the equity compensation tied to future clinical milestones and the need for stockholder approval for share reserve increase introduce some contingent elements and potential dilution.

Positives

• The appointment of Dr. Inderjit Kaul, an experienced global drug development leader with expertise in regulatory, clinical, and commercialization operations across multiple therapeutic areas, including neurology and schizophrenia, significantly strengthens the Company's board and clinical development capabilities.
• Dr. Kaul's recent experience overseeing the late-stage clinical development and commercialization of Cobenfy™ for schizophrenia is expected to be invaluable for the confirmatory Phase 3 trial of roluperidone.
• The Company is strategically adding board members with significant schizophrenia clinical trial experience, aligning with its recent $200 million private placement to advance roluperidone.
• Roluperidone targets negative symptoms of schizophrenia, which represents a significant unmet medical need with no currently FDA-approved treatments, indicating a substantial market opportunity.

Negatives

• The equity compensation for Dr. Kaul under the consulting agreement (0.7% of Share Total) is contingent on stockholder approval for an increase to the share reserve under the Company's Amended and Restated 2013 Equity Incentive Plan, indicating potential future dilution.
• A significant portion of Dr. Kaul's consultant options (75%) vests only upon the achievement of specific clinical trial milestones for roluperidone, introducing performance-based risk to the compensation structure.

Risks

• Future financial performance and position may not improve, potentially leading to difficulties in implementing the Company's business strategy and plans.
• The expected sufficiency of existing cash resources and runway may not be accurate, potentially requiring additional financing sooner than anticipated or leading to unexpected liquidity constraints.
• Internal and external costs for ongoing and planned activities may be higher than expected, which could cause the Company to use cash more quickly or to change/curtail some plans.
• Clinical trials and studies may be delayed, may not have satisfactory outcomes, and earlier trial results may not be predictive of later trials.
• The design and rate of enrollment for clinical trials, including the confirmatory Phase 3 trial evaluating roluperidone, may not enable successful completion.
• The commercial opportunity for roluperidone in negative symptoms of schizophrenia may be smaller than anticipated.
• The Company may be unable to obtain and maintain necessary regulatory approvals.
• Uncertainties are inherent in the initiation and completion of clinical trials and clinical development.
• The need to align with collaborators or partners may hamper or delay development and regulatory efforts or increase costs.
• Uncertainties exist regarding patent protection and potential litigation.
• General economic conditions could adversely affect the Company's operations and financial results.

Future Outlook

The company aims to progress roluperidone through a confirmatory Phase 3 trial for negative symptoms of schizophrenia, resubmit its New Drug Application (NDA) to the FDA, and prepare for a potential US commercial launch, if approved. The appointment of Dr. Kaul is expected to strengthen clinical operations and support the execution of the Phase 3 trial.

Management Comments

• "I am delighted to welcome Dr. Inderjit Kaul to our board of directors at this key stage in the development of roluperidone for the treatment of negative symptoms of schizophrenia." Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva Neurosciences.
• "Dr. Kaul is an experienced and successful global drug development leader, with expertise in regulatory, clinical and commercialization operations, in multiple therapeutic areas including, neurology, oncology and immunology." Dr. Remy Luthringer.
• "His recent experience overseeing the late-stage clinical development and commercialization of CobenfyTM, for the treatment of schizophrenia, will be invaluable as we prepare and execute the confirmatory study in negative symptoms of schizophrenia with roluperidone." Dr. Remy Luthringer.
• "I am pleased to be joining Minerva Neurosciences at such an important time." Dr. Inderjit Kaul.
• "Negative symptoms in schizophrenia is a significant unmet need and there are currently no FDA approved treatments for those patients with impairing negative symptoms." Dr. Inderjit Kaul.
• "I look forward to working with the Minerva Neurosciences team to progress roluperidone through a confirmatory phase 3 trial and, if approved, bringing this treatment to patients." Dr. Inderjit Kaul.

Industry Context

The appointment of Dr. Kaul, with his extensive background in neuropsychiatry and successful development of a schizophrenia treatment (CobenfyTM), positions Minerva Neurosciences to leverage specialized expertise in a highly competitive and challenging therapeutic area. The focus on negative symptoms of schizophrenia addresses a significant unmet medical need, as current FDA-approved antipsychotics primarily target positive symptoms, leaving a substantial market gap for effective treatments for primary negative symptoms.

Comparison to Industry Standards

• Dr. Kaul's experience includes overseeing late-stage clinical development and commercialization of CobenfyTM for schizophrenia at Bristol Myers Squibb.
• He also led the development of a muscarinic agonist at Karuna Therapeutics, which resulted in FDA approval of CobenfyTM. This direct experience with a recently approved schizophrenia drug provides a strong benchmark for Minerva's roluperidone development.
• The company is targeting negative symptoms of schizophrenia, an area where there are currently no FDA-approved treatments, indicating a potential first-in-class opportunity if successful, which would set a new industry standard.

Management Changes

Corporate Governance

Related Party Transactions

• A Consulting Agreement dated November 14, 2025, was entered into between Minerva Neurosciences, Inc. and Inderjit Kaul, M.D., MPH, who is also a newly appointed director. This transaction is explicitly disclosed as required by Item 404(a) of Regulation S-K.

Stakeholder Impact

• Shareholders face potential dilution from the initial option grant to Dr. Kaul (9,500 shares) and the consultant option (0.7% of Share Total), which requires stockholder approval for an increase in the share reserve. The success of roluperidone's Phase 3 trial, which Dr. Kaul will assist with, could significantly impact share value.
• Patients suffering from schizophrenia, particularly those with negative symptoms, could benefit from a new treatment option if roluperidone successfully completes its clinical trials and gains regulatory approval, addressing a significant unmet medical need.
• Employees and management are expected to benefit from the enhanced clinical expertise and strategic guidance provided by Dr. Kaul, which aims to strengthen clinical operations and accelerate the development of roluperidone.

Next Steps

• Conduct the confirmatory Phase 3 trial for roluperidone in schizophrenia.
• Seek stockholder approval at the 2025 Annual Meeting for an increase to the share reserve under the Amended and Restated 2013 Equity Incentive Plan.
• Publicly announce achievement of the primary endpoint of the Phase 3 confirmatory trial of roluperidone at the 12-week timepoint.
• Publicly announce safety data from the 40-week relapse assessment phase of the trial.
• Resubmit the New Drug Application (NDA) for roluperidone to the FDA.
• Prepare for US commercial launch of roluperidone, if approved.
• Dr. Kaul will become eligible to receive Annual Grants beginning with the Company's 2026 Annual Meeting of Stockholders.

Key Dates

Recommendation

The appointment of Dr. Kaul, a highly experienced professional in schizophrenia drug development, is a positive development that strengthens the company's clinical expertise. This aligns with the recent $200 million capital raise aimed at advancing roluperidone through its confirmatory Phase 3 trial for an unmet medical need. However, the significant equity compensation tied to future clinical milestones and the need for stockholder approval for share reserve increase introduce elements of risk and potential dilution. The company's future remains heavily dependent on the successful execution and outcomes of the roluperidone Phase 3 trial, making a 'hold' recommendation appropriate until more definitive clinical data emerges.

Keywords

Minerva Neurosciences, NERV, Board Appointment, Inderjit Kaul, Schizophrenia, Roluperidone, Phase 3 Trial, Clinical Development, Biopharmaceutical, CNS Disorders, Corporate Governance, Director Compensation, Consulting Agreement, Equity Incentive Plan, FDA Approval, Negative Symptoms